

10/612,650

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul21zxn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
fields
NEWS 5 AUG 02 Cplus and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
status data from INPADOC
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 12 SEP 27 STANDARDS will no longer be available on STN
NEWS 13 SEP 27 SWETSCAN will no longer be available on STN
NEWS 14 OCT 28 KOREAPAT now available on STN

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:05:00 ON 04 NOV 2004

=> file reg

10/612,650

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:05:08 ON 04 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 NOV 2004 HIGHEST RN 774165-06-9
DICTIONARY FILE UPDATES: 2 NOV 2004 HIGHEST RN 774165-06-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\STNEXP4\QUERIES\10612650.str



chain nodes :

18 19 21 22 23

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

1-19 10-18 13-23 15-22 19-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13
13-14 13-15 14-17 15-16 16-17

exact/norm bonds :

1-19 7-11 8-14 10-18 11-12 12-13 13-14 13-15 13-23 14-17 15-16 15-22
16-17 19-21

normalized bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

10/612,650

G1:H,S

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
21:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> dis l1

L1 HAS NO ANSWERS

L1 STR



G1 H,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

SAMPLE SEARCH INITIATED 13:05:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1427 TO ITERATE

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 26274 TO 30806

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:05:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 29600 TO ITERATE

100.0% PROCESSED 29600 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01


L3 5 SEA SSS FUL L1

=> dis 1-5

10/612,650

L3 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN
RN 756815-77-7 REGISTRY
CN Estra-1,3,5,7,9-pentaen-17-one, 6-hydroxy-3-(sulfooxy)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 O6 S
CI COM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN
RN 591233-37-3 REGISTRY
CN Estra-1,3,5,7,9-pentaen-17-one, 6-hydroxy-3-(sulfooxy)-, monosodium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 O6 S . Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CRN (756815-77-7)

Absolute stereochemistry.



● Na

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN
RN 361145-18-8 REGISTRY
CN Estra-1,3,5,7,9-pentaen-17-one, 3,6-dihydroxy-, hydrogen sulfate, sodium salt (9CI) (CA INDEX NAME)


OTHER NAMES:

CN 6-Hydroxyequilenin sulfate sodium salt
FS STEREOSEARCH
MF C18 H18 O3 . x H2 O4 S . x Na
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)

CM 1

CRN 360792-47-8
CMF C18 H18 O3

Absolute stereochemistry.




CM 2

CRN 7664-93-9

10/612,650

CMF H2 O4 S




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN
RN 361145-16-6 REGISTRY
CN Estra-1,3,5,7,9-pentaen-17-one, 3,6-dihydroxy-, hydrogen sulfate (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN 6-Hydroxyequilenin sulfate
FS STEREOSEARCH
MF C18 H18 O3 . x H2 O4 S
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

CM 1


CRN 360792-47-8
CMF C18 H18 O3

Absolute stereochemistry.



CM 2


CRN 7664-93-9
CMF H2 O4 S



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 360792-47-8 REGISTRY
 CN Estra-1,3,5,7,9-pentaen-17-one, 3,6-dihydroxy- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 6-Hydroxyequilenin
 FS STEREOSEARCH
 MF C18 H18 O3
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
164.69	164.90

FILE 'HCAPLUS' ENTERED AT 13:06:10 ON 04 NOV 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Nov 2004 VOL 141 ISS 19
FILE LAST UPDATED: 3 Nov 2004 (20041103/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 10 L3

=> s 14 and pd<july 2002

22376714 PD<JULY 2002

(PD<20020700)

L5 2 L4 AND PD<JULY 2002

=> dis 15 1-2 bib abs

L5 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:693340 HCAPLUS

DN 135:237103

TI 6-Oxygenated steroidal estrogens with aromatic A and B rings, pharmaceutical formulations containing the estrogens, and their uses

IN Hill, Edward N.; Sancilio, Frederick D.; Whittle, Robert R.

PA Endeavor Pharmaceuticals, USA

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068669	A1	20010920	WO 2001-US7544	20010309 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002016316	A1	20020207	US 2001-800614	20010308 <--
	US 6660726	B2	20031209		
	EP 1263770	A1	20021211	EP 2001-920261	20010309
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003207855	A1	20031106	US 2003-438585	20030515

10/612,650

US 2004147496 A1 20040729 US 2003-628057 20030723
 PRAI US 2000-188533P P 20000310
 US 2001-800614 A1 20010308
 WO 2001-US7544 W 20010309
 OS MARPAT 135:237103
 GI



I

AB Novel estrogenic compds. of formula (I) are provided, wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucuronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucuronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an α or a β orientation. Pharmaceutical compns. containing the compds. of the invention are also provided as are methods of treating mammals in need of treatment using compds. of the present invention. Examples of conditions that can be treated by the compns. of the invention are vasomotor symptoms, atrophic vaginitis, and osteoporosis.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:693071 HCAPLUS
 DN 135:237102
 TI Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
 IN Hill, Edward N.; Leonard, Thomas W.; Sancilio, Frederick D.; Schlipp, Katherin M.; Shirazi, Dean G.; Whittle, Robert R.
 PA Endeavor Pharmaceuticals, USA
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068074	A2	20010920	WO 2001-US6884	20010305 <--
	WO 2001068074	A3	20020321		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1267852 A2 20030102 EP 2001-918326 20010305
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004500396 T2 20040108 JP 2001-566638 20010305
 PRAI US 2000-524132 A 20000310
 WO 2001-US6884 W 20010305
 AB A composition of matter is provided having a mixture of active estrogenic
 compds.

The mixture is present in CP form. The mixture includes salts of conjugated
 estrone, conjugated equilin, conjugated $\Delta 8,9$ -dehydroestrone,
 conjugated 17α -estradiol, conjugated 17α -dihydroequilin,
 conjugated 17α -dihydroequilin, conjugated 17β -estradiol,
 conjugated equilenin, conjugated 17α -dihydroequilenin, and
 conjugated 17β -dihydroequilenin. The mixture also contains the same
 essential estrogenic compds. present in naturally derived equine
 conjugated estrogens. Drug products including the composition of matter are
 also provided, as are methods of using these drug products to treat
 mammals in need of treatment. Methods of analyzing mixts. containing
 conjugated estrogens are also provided.

=> s 14 not 15

L6 8 L4 NOT L5

=> dis 16 1-8 bib abs

L6 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:822887 HCAPLUS

DN 141:314487

TI Preparation of estrogenic compounds via heat treatment of conjugated
 estrogens in high humidity for treating estrogen deprivation

IN Hill, Edward N.; Leonard, Thomas W.; Whittle, Robert R.

PA Barr Laboratories, Inc., USA

SO Eur. Pat. Appl., 21 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 1464650	A2	20041006	EP 2004-8154	20040402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2004198670	A1	20041007	US 2003-407509	20030404
PRAI	US 2003-407509	A	20030404		
GI					



AB The present invention relates to the preparation of novel estrogenic compds., such as I [R1 = peroxy, OH, halo, SH; R2 = glucuronide, sulfate, pyrophosphate; R3 = OH, ester, ketone], via heating of $\Delta^{8,9}$ -dehydroestrone sodium sulfate between 30° to 60° C in high humidity. Method of analyzing mixts. containing conjugated estrogens are also provided. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic compds.

L6 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:182591 HCAPLUS

DN 140:235934

TI Preparation of 6-hydroxyequilenin derivatives as estrogenic agent

IN Megati, Sreenivasulu; Vid, Galina; Mohan, Arthur G.; Raveendranath, Panolil; Potoski, John

PA Wyeth, John, and Brother Ltd., USA

SO U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO



DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004044234	A1	20040304	US 2003-612650	20030702
PRAI	US 2002-393424P	P	20020702		

GI



AB This invention relates to preparation of 6-hydroxyequilenin derivs., such as I [R1 = OH; R2 = H; R1R2 = O], a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a sulfate ester or a glucuronide of the hydroxyl group at the 3- or 17-position, for their therapeutic use as estrogenic agents. The prepared compds. bind to both subtypes of estrogen receptors (ER α and ER β), although in general they are selective

for ER β . Thus, 6-hydroxyequilenin derivative II was prepared via a multistep sequence starting from 6-keto-7-bromo-17 β -estradiol-diacetate. In a test for binding to human recombinant estrogen receptors in vitro, II bound to ER α and ER β with IC₅₀ values of 2183 nM and 123 nM, resp.

L6 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:818295 HCAPLUS
 DN 139:302513
 TI Hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause
 IN Leonard, Thomas W.; Waldon, R. Forrest
 PA Endeavor Pharmaceuticals, USA
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084547	A1	20031016	WO 2003-US2873	20030131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003216366	A1	20031120	US 2003-356242	20030131
PRAI US 2002-369905P	P	20020403		

AB The present invention includes methods for treating vasomotor symptoms associated with human menopause through the administration of estrogenic compds. The methods presented may include starting estrogen therapy at a high dose, and then lowering the dose once therapy has been shown to be effective. Progestins and androgenic compound can addnl. be combined with the therapy.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:796313 HCAPLUS
 DN 139:271455
 TI Estrogens and non-aromatizing androgens pharmaceutical compositions for the treatment of frailty and sexual dysfunction of women undergoing estrogen replacement therapy
 IN Leonard, Thomas W.; Waldon, R. Forrest
 PA USA
 SO U.S. Pat. Appl. Publ., 8 pp.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003191096	A1	20031009	US 2002-268008	20021009
WO 2003084546	A1	20031016	WO 2003-US2871	20030131

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-369635P P 20020403
US 2002-268008 A 20021009

AB The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat frailty and sexual dysfunction in women undergoing estrogen replacement therapy.

L6 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:696534 HCAPLUS

DN 139:214619

TI Preparation of 6-hydroxyequilenin derivatives as estrogenic agents

IN Harris, Heather A.; Keith, James C.; Albert, Leo M.; Vid, Galina; Megati, Sreenivasulu; Miller, Christopher P.

PA Wyeth, John, and Brother Ltd., USA

SO U.S. Pat. Appl. Publ., 19 pp.



CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003166627	A1	20030904	US 2003-348510	20030121
PRAI	US 2002-351282P	P	20020123		
OS	MARPAT 139:214619				
GI					



AB This invention provides preparation of 6-hydroxyequilenin derivs., such as I [R1 = H, alkyl, benzyl, alkylcarbonyl, benzoyl; R2 = OH, alkoxy, benzyloxy, alkylcarboxy; R3 = H, alkyl, OH, alkoxy; R2R3 = O], a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a sulfate ester or a glucuronide of the hydroxyl group at the 3- or 17-position, for their therapeutic use as estrogenic agents. The prepared compds. bind to both subtypes of estrogen receptors (ER α and ER β), although in general they are selective for ER β . Thus, 6-hydroxyequilenin derivative II was prepared via a multistep sequence starting from 6-keto-7-bromo-17 β -estradiol-diacetate. In a test for binding

to human recombinant estrogen receptors in vitro, II bound to ER α and ER β with IC50 values of 2183 nM and 123 nM, resp.

L6 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:888571 HCAPLUS
 DN 137:363705
 TI Treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens
 IN Leonard, Thomas W.
 PA Endeavor Pharmaceuticals, USA
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092102	A2	20021121	WO 2002-US15690	20020516
	WO 2002092102	A3	20030320		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003004145	A1	20030102	US 2002-147366	20020516
	EP 1390038	A2	20040225	EP 2002-736946	20020516
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2004072808	A1	20040415	US 2003-678828	20031003
PRAI	US 2001-291488P	P	20010516		
	US 2002-147366	A1	20020516		
	WO 2002-US15690	W	20020516		

AB A method of treating vasomotor symptoms associated with hormone deficiencies is claimed comprising: administering a dose of a therapeutic amount of an estrogenic compound to a subject; administering a dose of a therapeutic amount of a progestin agent to a subject; and administering a second dose of a therapeutic amount of a progestin agent at a later time period to the subject, said second dose comprising a lower dosage of said therapeutic amount of a progestin agent than said first dose. The method further comprises administering an androgen compound in a daily dose. The method can be used for treating hormonal deficiencies, including menopause. Also claimed is a method of preventing endometrial hyperplasia associated with estrogen therapy in a subject, said method comprising: administering continuously and uninterruptedly for a first predetd. time period a first dose of a progestin agent to said subject; and administering continuously and uninterruptedly for a second predetd. time period a second dose of a progestin agent to said subject.

L6 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:574935 HCAPLUS
 DN 137:120059
 TI Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
 IN Leonard, Thomas W.; Waldon, R. Forrest
 PA Endeavor Pharmaceuticals, USA

SO PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058706	A2	20020801	WO 2001-US51045	20011221
	WO 2002058706	A3	20030313		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002151530	A1	20021017	US 2001-29424	20011220
	EP 1343509	A2	20030917	EP 2001-989306	20011221
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004520375	T2	20040708	JP 2002-559040	20011221
	US 2003195177	A1	20031016	US 2003-424243	20030429
PRAI	US 2000-258142P	P	20001222		
	US 2001-29424	A3	20011220		
	WO 2001-US51045	W	20011221		

AB The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat hormonal deficiencies in women undergoing estrogen replacement therapy. The combined estrogen and non-aromatizing androgen therapy has less of a detrimental effect on the uterus than traditional estrogen replacement therapy. A progestin may also be administered along with the estrogen and the androgen. Pharmaceutical compns. are claimed along with the method of treatment.

L6 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:504629 HCAPLUS

DN 137:83634

TI Estrogen, androgen and vasodilator compositions for the treatment of female sexual dysfunction

IN Leonard, Thomas W.; Waldon, R. Waldon

PA Endeavor Pharmaceuticals, USA

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002051420	A2	20020704	WO 2001-US49978	20011221
	WO 2002051420	A3	20021227		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

10/612,650

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002107230 A1 20020808 US 2001-29423 20011220
EP 1359920 A2 20031112 EP 2001-992297 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004520320 T2 20040708 JP 2002-552564 20011221
PRAI US 2000-257745P P 20001222
WO 2001-US49978 W 20011221
AB A pharmaceutical composition for the treatment of sexual dysfunction,
particularly post-menopausal females, is provided. The composition includes a
therapeutically effective amount of an estrogenic compound, androgenic
compound,
vasodilation compound, and a pharmaceutically acceptable carrier. Tablets
were prepared containing and estrogen such as estradiol, an androgen such as
methyltestosterone and a vasodilator such as phentolamine and excipients.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
30.22	195.12

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-7.00	-7.00

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:07:15 ON 04 NOV 2004